Primary Myelofibrosis

Lupus Nephritis

IFNα-Kinoid

Lupus : A major unmet medical need Lupus is a chronic and severe autoimmune disease in which the immune system produces antibodies to cells within the body leading to widespread inflammation and t...

Systemic lupus erythematosus

Lupus is a systemic autoimmune disease that can affect any part of the body. As with other autoimmune diseases, the immune system attacks the body’s cells and tissue resulting in inflammation...

Variant Forms of Lupus

Myelofibrosis drug Jakavi (ruxolitinib) gets EU approval

ZURICH (Reuters - Swiss drugmaker Novartis AG has received approval from the European Commission for Jakavi (ruxolitinib), for the treatment of disease-related splenomegaly or symptoms in adult pa...

World Lupus Day: Lupus organizations to rally together to raise awareness of lupus

The Lupus Foundation of America and lupus organizations around the globe are rallying together on May 10, World Lupus Day, to urge action and raise awareness of lupus, a mysterious and devastating dis...

First myelofibrosis drug, Novartis' Jakavi, approved in Europe

Swiss drug major Novartis (NOVN: VX) received approval yesterday from the European Commission for Jakavi (INC424, ruxolitinib), a JAK 1 and JAK 2 inhibitor for the treatment of disease-related splenom...

Novartis receives EC approval for Jakavi to treat myelofibrosis

Incyte Corporation today announced that its strategic collaborator, Novartis, received approval from the European Commission for Jakavi (INC424, ruxolitinib), an oral JAK 1 and JAK 2 inhibitor discove...

Lupus Treatment | How “Lupus Bible” Helps People Get Rid Of Lupus Condition Permanently – Tony Nguyen

Seattle, Wa (PRWEB) March 08, 2013 Lupus Bible is the new achievement of Julia Liu, who claims to give people the lupus treatment to help them get rid of their lupus disease permanently and natur...

Patient perspectives: Tiffany Peterson

Tiffany Peterson (also known as Tiffany and Lupus) shares what it is like to be a patient with Lupus and how pharma can better work with patients such as her. Frustrated with the lack of information...

Barriers to overcome in lupus drug development

It has taken the lupus research community over 50 years to produce a new therapy. Although it is now a year old, Benlysta (belimumab), now marketed by GlaxoSmithKline and Human Genome Sciences, is the...

Lupus Research Institute awards first $1M private sector grants to uncover lupus causes

(Lupus Research Institute) The Lupus Research Institute announced the first $1 million privately funded research grants given to lupus investigators. The LRI Distinguished Innovator Initiative was cr...

Idiopathic Myelofibrosis in an Infant.

Idiopathic Myelofibrosis (MF) is an extremely rare condition in children. It has a very variable clinical spectrum. Cases of secondary myelofibrosis associated with Vitamin D deficiency and Systemic L...

Ruxolitinib.

In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediat...

MYELOFIBROSIS IN CHILDREN: Experience at a Single Tertiary Care Center in India.

The authors describe 10 cases of myelofibrosis diagnosed and managed at their center over 16 years. There were 2 and 8 cases, respectively, of primary and secondary myelofibrosis. All patients present...

Differential diagnosis of myelofibrosis based on WHO 2008 criteria: Acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis.

INTRODUCTION: The aim of this study was to characterize clinicopathological features of acute panmyelosis with myelofibrosis (APMF), acute megakaryoblastic leukemia with myelofibrosis (AMKL-MF), prima...

The face of lupus.

ABSTRACT: Systemic lupus erythematosus-a chronic, complex autoimmune disease without a defi nitive diagnostic test-often requires burdensome procedures to confi rm diagnosis. Nurse practitioners must...